右美托咪定对肥胖患者保留自主呼吸七氟醚吸入诱导置入BlockBuster喉罩影响的对比研究

注册号:

Registration number:

ChiCTR1800016868 

最近更新日期:

Date of Last Refreshed on:

2018-06-30 04:27:38 

注册时间:

Date of Registration:

2018-06-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定对肥胖患者保留自主呼吸七氟醚吸入诱导置入BlockBuster喉罩影响的对比研究

Public title:

A comparative study on the effects of dexmedetomidine on the inhalation of sevoflurane for BlockBuster laryngeal mask insertion in obese patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定对肥胖患者保留自主呼吸七氟醚吸入诱导置入BlockBuster喉罩影响的对比研究

Scientific title:

A comparative study on the effects of dexmedetomidine on the inhalation of sevoflurane for BlockBuster laryngeal mask insertion in obese patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

万磊 

研究负责人:

万磊 

Applicant:

Wan Lei 

Study leader:

Wan Lei 

申请注册联系人电话:

Applicant telephone:

+86 13401067838

研究负责人电话:

Study leader's
telephone:

+86 13401067838

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wanleimz@sina.com

研究负责人电子邮件:

Study leader's E-mail:

wanleimz@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区永安路95号北京友谊医院麻醉科

研究负责人通讯地址:

北京市西城区永安路95号北京友谊医院麻醉科

Applicant address:

95 Yong'an Road, Xicheng District, Beijing, China

Study leader's address:

95 Yong'an Road, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京友谊医院

Applicant's institution:

Beijing Friendship Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京友谊医院麻醉科

Affiliation of the Leader:

Beijing Friendship Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018-P2-079-01

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

首都医科大学附属北京友谊医院伦理委员会

Name of the ethic committee:

The Ethics Committee of Beijing Friendship Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-06-28 00:00:00

伦理委员会联系人:

李悦

Contact Name of the ethic committee:

Li Yue

伦理委员会联系地址:

北京市西城区永安路95号北京友谊医院

Contact Address of the ethic committee:

Beijing Friendship Hospital, 95 Yong'an Road, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京友谊医院

Primary sponsor:

Beijing Friendship Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区永安路95号

Primary sponsor's address:

95 Yong'an Road, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院

具体地址:

北京市西城区永安路95号

Institution
hospital:

Beijing Friendship Hospital, Capital Medical University

Address:

95 Yong'an Road, Xicheng District, Beijing

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

肥胖  

Target disease:

obesity

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对比观察右美托咪定对保留自主呼吸七氟醚吸入诱导置入BlockBuster喉罩ED50及喉罩置入条件分级的影响,为肥胖患者保留自主呼吸吸入诱导置入喉罩提供理论依据。  

Objectives of Study:

To compare the effects of dexmetomidine on the ED50 of sevoflurane and the grading of conditions for LMA insertion induced by sevoflurane with spontaneous breathing in obese patients, to provide a theoretical basis for spontaneous breathing inhalation induction for LMA insertion in obese patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①未控制的高血压,心肌梗死,缺血性心肌病,心动过缓或服用β受体阻滞剂者;②张口度<3cm,颈部放射损伤或肿瘤,颈椎不稳定的患者;③上气道疾患,如占位、2周内有上呼吸道感染史,或有出血倾向;④对丙泊酚或七氟醚过敏者;⑤高反流误吸风险。

Exclusion criteria:

1. uncontrolled high blood pressure, myocardial infarction, ischemic cardiomyopathy, bradycardia or taking beta-blockers;
2. cases of mouth <3cm, neck injury or tumor, unstable cervical spine;
3. Airway disorders, such as occupancy, history of upper respiratory tract infection within 2 weeks, or bleeding tendency;
4. allergic to propofol or sevoflurane;
5. risk of high reflux aspiration.

研究实施时间:

Study execute time:

From 2018-07-01 00:00:00 To 2019-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-07-01 00:00:00 To 2019-11-30 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

72

Group:

Group 1

Sample size:

干预措施:

七氟醚

干预措施代码:

Intervention:

Sevflurane

Intervention code:

组别:

2组

样本量:

72

Group:

Group 2

Sample size:

干预措施:

七氟醚联合右美托咪定

干预措施代码:

Intervention:

Sevflurane and dexmetomidine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Friendship Hospital affiliated to Capital Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

喉罩置入时体动

指标类型:

主要指标

Outcome:

Body movement wen LMA insertion

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

喉罩置入条件分级

指标类型:

主要指标

Outcome:

grading of conditions for LMA insertion

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

用Excel软件生成随机码,放入不透明信封,在实施试验前由助手打开信封,选择相应的麻醉方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

Use Excel software to generate a random code, place the opaque envelope, open the envelope by an assistant before performing the test, and select the appropriate anesthetic method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

病例记录表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

CRF

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2018-06-30 04:27:38